252 related articles for article (PubMed ID: 29383482)
1. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study.
Ohnuma H; Sato Y; Hirakawa M; Kikuchi S; Miyanishi K; Sagawa T; Takahashi Y; Nobuoka T; Okamoto K; Miyamoto H; Takemasa I; Takayama T; Kato J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):539-548. PubMed ID: 29383482
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).
Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y;
Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179
[TBL] [Abstract][Full Text] [Related]
6. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
[TBL] [Abstract][Full Text] [Related]
7. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Kanazawa Y; Kato S; Fujita I; Onodera H; Uchida E
J Nippon Med Sch; 2013; 80(5):378-83. PubMed ID: 24189356
[TBL] [Abstract][Full Text] [Related]
9. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Arai H; Iwasa S; Boku N; Kawahira M; Yasui H; Masuishi T; Muro K; Minashi K; Hironaka S; Fukuda N; Takahari D; Nakajima TE
BMC Cancer; 2019 Jul; 19(1):652. PubMed ID: 31269916
[TBL] [Abstract][Full Text] [Related]
10. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Shitara K; Mizota A; Matsuo K; Sato Y; Kondo C; Takahari D; Ura T; Tajika M; Muro K
Gastric Cancer; 2013 Jan; 16(1):48-55. PubMed ID: 22362376
[TBL] [Abstract][Full Text] [Related]
11. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
[TBL] [Abstract][Full Text] [Related]
12. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
Mieno H; Yamashita K; Hosoda K; Moriya H; Higuchi K; Azuma M; Komori S; Yoshida T; Tanabe S; Koizumi W; Katada N; Watanabe M
Surg Today; 2017 Oct; 47(10):1249-1258. PubMed ID: 28365892
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
17. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
[TBL] [Abstract][Full Text] [Related]
19. [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
Hamakawa T; Kurokawa Y; Takiguchi S; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Mori M; Dok Y
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2342-4. PubMed ID: 22202376
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo H; Yu Z; Gao H; Guan C; Xu M
J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
